by The global lung disease therapeutics market size accounted for US$ 81.2 Bn in 2022 and is projected to reach around USD 146.1 Bn by 2032, growing at a CAGR of 6.04% from 2023 to 2032.
Report Summary
The global lung disease therapeutics market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the lung disease therapeutics market across the globe.
A comprehensive estimate on the lung disease therapeutics market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of lung disease therapeutics during the forecast period. Price point comparison by region with global average price is also considered in the study.
Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2927
Lung Disease Therapeutics Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 86.11 Billion |
| Market Size by 2032 | USD 146.1 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 6.04% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Disease Type, By Drug Class, By Molecule Type, By Distribution Channel, and By Treatment Type |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Key Highlights:
Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized lung disease therapeutics market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.
Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.
Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.
Also Read: High Performance Alloys Market Size To Cross USD 16.7 Bn By 2032
Lung Disease Therapeutics Market Players
The report includes the profiles of key lung disease therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.
Major companies operating in this area
- Johnson & Johnson
- Amgen Inc.
- AstraZeneca
- Boehringer Ingelheim
- Pfizer Inc.
- Allergan Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Hoffmann-La Roche
- Merck & Co
- Teva Pharmaceutical Industries Ltd.
- AbbVie, Inc.
- Novartis AG
Market Segmentation
By Disease Type
- Asthma
- Lung Cancer
- Chronic Obstructive Pulmonary Disease (COPD)
By Drug Class
- Corticosteroids
- Bronchodilator
- Antimicrobial
- Alkylating Agents
- Mucolytics
By Molecule Type
- Small molecules
- Biologics
By Treatment Type
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Radiation Therapy
By Distribution Channel
- Online
- Hospital
- Retail
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Lung Disease Therapeutics Market
5.1. COVID-19 Landscape: Lung Disease Therapeutics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Lung Disease Therapeutics Market, By Disease Type
8.1. Lung Disease Therapeutics Market, by Disease Type, 2023-2032
8.1.1. Asthma
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Lung Cancer
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Chronic Obstructive Pulmonary Disease (COPD)
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Lung Disease Therapeutics Market, By Drug Class
9.1. Lung Disease Therapeutics Market, by Drug Class, 2023-2032
9.1.1. Corticosteroids
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Bronchodilator
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Antimicrobial
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Alkylating Agents
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Mucolytics
9.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Lung Disease Therapeutics Market, By Molecule Type
10.1. Lung Disease Therapeutics Market, by Molecule Type, 2023-2032
10.1.1. Small molecules
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Biologics
10.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Lung Disease Therapeutics Market, By Treatment Type
11.1. Lung Disease Therapeutics Market, by Treatment Type, 2023-2032
11.1.1. Chemotherapy
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Immunotherapy
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Targeted Therapy
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Radiation Therapy
11.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Lung Disease Therapeutics Market, By Distribution Channel
12.1. Lung Disease Therapeutics Market, by Distribution Channel, 2023-2032
12.1.1. Online
12.1.1.1. Market Revenue and Forecast (2020-2032)
12.1.2. Hospital
12.1.2.1. Market Revenue and Forecast (2020-2032)
12.1.3. Retail
12.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 13. Global Lung Disease Therapeutics Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.1.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.1.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.1.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.1.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.1.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.1.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.1.6.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.1.6.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.1.7.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.1.7.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.1.7.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.1.7.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.2.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.2.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.2.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.2.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.2.7. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.2.8. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.2.9.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.9.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.2.10. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.2.11. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.2.12.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.12.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.2.12.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.2.13. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.2.14.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.2.14.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.2.14.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.2.15. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.3.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.3.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.3.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.3.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.3.6.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.3.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.3.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.8.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.3.8.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.3.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.3.10.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.10.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.3.10.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.3.10.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.3.11.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.3.11.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.3.11.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.3.11.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.4.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.4.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.4.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.4.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.4.6.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.4.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.4.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.8.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.4.8.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.4.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.4.10.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.10.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.4.10.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.4.10.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.4.11.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.4.11.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.4.11.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.4.11.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.5.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.5.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.5.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.5.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.5.6.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.5.6.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.5.6.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.5.7. Market Revenue and Forecast, by Distribution Channel (2020-2032)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Disease Type (2020-2032)
13.5.8.2. Market Revenue and Forecast, by Drug Class (2020-2032)
13.5.8.3. Market Revenue and Forecast, by Molecule Type (2020-2032)
13.5.8.4. Market Revenue and Forecast, by Treatment Type (2020-2032)
13.5.8.5. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 14. Company Profiles
14.1. Johnson & Johnson
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Amgen Inc.
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. AstraZeneca
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Boehringer Ingelheim
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Pfizer Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Allergan Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Bristol-Myers Squibb Company
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Eli Lilly and Company
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Hoffmann-La Roche
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Merck & Co
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
